ProCE Banner Activity

DESTINY-PanTumor01: Phase II Study of Trastuzumab Deruxtecan in Patients With HER2-Activating Mutations in Solid Tumors

Conference Coverage

In the DESTINY-PanTumor01 phase II trial, efficacy and safety of T-DXd in patients with solid tumors harboring a prespecified HER2 activating mutation was promising and warrants further study.

Released: November 01, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc